Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Snape

Showing results (81-90 of 169) with videos related to

Pageof 17
Sort By:
Vaccine|May 10, 2017
Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]Mildred A Iro, Matthew D Snape, Merryn Voysey, et al.
Vaccine|July 14, 2020
Randomized clinical trial of DTaP5-HB-IPV-Hib vaccine administered concomitantly with meningococcal serogroup C conjugate vaccines during the primary infant seriesJennifer L Oliver, Christine Sadorge, Florence Boisnard, et al.
BMJ Open|October 23, 2020
'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescentsJeremy Carr, Emma Plested, Parvinder Aley, et al.
The Pediatric Infectious Disease Journal|July 2, 2019
Attitudes of Pregnant Women and Healthcare Professionals Toward Clinical Trials and Routine Implementation of Antenatal Vaccination Against Respiratory Syncytial Virus: A Multicenter Questionnaire StudyChristopher R Wilcox, Anna Calvert, Jane Metz, et al.
BMC Pediatrics|February 9, 2019
Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized studySaul N Faust, Maguelone Le Roy, Chitsanu Pancharoen, et al.
The Journal of Infectious Diseases|October 19, 2022
Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 MonthsArabella S V Stuart, Miia Virta, Kristi Williams, et al.
Vaccine|September 19, 2009
Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adultsIsabel Leroux-Roels, Marie Van der Wielen, Froukje Kafeja, et al.
The Lancet. Infectious Diseases|January 11, 2021
Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trialKimberly Davis, Marta Valente Pinto, Nick J Andrews, et al.
Pediatrics|August 3, 2018
Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic FunctionFederico Martinón-Torres, Ewa Bernatowska, Anna Shcherbina, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 25, 2019
First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy AdultsPaola Cicconi, Claire Jones, Esha Sarkar, et al.
Pageof 17

Showing results (81-90 of 169) with videos related to

Sort By:
Pageof 17
Vaccine|May 10, 2017
Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]Mildred A Iro, Matthew D Snape, Merryn Voysey, et al.
Vaccine|July 14, 2020
Randomized clinical trial of DTaP5-HB-IPV-Hib vaccine administered concomitantly with meningococcal serogroup C conjugate vaccines during the primary infant seriesJennifer L Oliver, Christine Sadorge, Florence Boisnard, et al.
BMJ Open|October 23, 2020
'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescentsJeremy Carr, Emma Plested, Parvinder Aley, et al.
The Pediatric Infectious Disease Journal|July 2, 2019
Attitudes of Pregnant Women and Healthcare Professionals Toward Clinical Trials and Routine Implementation of Antenatal Vaccination Against Respiratory Syncytial Virus: A Multicenter Questionnaire StudyChristopher R Wilcox, Anna Calvert, Jane Metz, et al.
BMC Pediatrics|February 9, 2019
Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized studySaul N Faust, Maguelone Le Roy, Chitsanu Pancharoen, et al.
The Journal of Infectious Diseases|October 19, 2022
Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 MonthsArabella S V Stuart, Miia Virta, Kristi Williams, et al.
Vaccine|September 19, 2009
Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adultsIsabel Leroux-Roels, Marie Van der Wielen, Froukje Kafeja, et al.
The Lancet. Infectious Diseases|January 11, 2021
Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trialKimberly Davis, Marta Valente Pinto, Nick J Andrews, et al.
Pediatrics|August 3, 2018
Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic FunctionFederico Martinón-Torres, Ewa Bernatowska, Anna Shcherbina, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 25, 2019
First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy AdultsPaola Cicconi, Claire Jones, Esha Sarkar, et al.
Pageof 17